Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology & Medical Chemistry II > Exam 2: Lecture X, Oral Hypoglycemic Agents > Flashcards

Exam 2: Lecture X, Oral Hypoglycemic Agents Flashcards

You may prefer our related Brainscape-certified flashcards:
USMLE® Step 1 flashcards AP® Chemistry flashcards Periodic Table flashcards Chemistry 101 flashcards Organic Chemistry 101 flashcards
1
Q

Oral Hypoglycemic agents used…

A

in patients with type 2 diabetes if cannot be managed by diet

pt who develop diabetes after 40 respond well

combo w/insulin maybe required

** should not be given to type 1**

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type 2 diabetes has insulin secreted only during….

A

phase 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Sulfonylureas

A

developed as a result of finding that sulfonamide derivative produced decreased blood glucose levels

had their effect by stimulating insulin release from pancreatic beta cells, functional islet cells are important

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sulfonylurea MOA

A

stimulate insulin secretin from beta-cells
possibly sensitize beta-cells to glucose
increase activity/number of peripheral insulin receptors
possible reduce glucagon secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sulfonylureas therapeutic uses

A

Type 2, 50-80% pt initially respond well

with chronic admin, reduced glucose levels maintained

cannot prevent longterm complications of diabetes

Sulfonylurea + suboptimal insulin = therapy Type 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Sulfonylureas pharmacokinetics

A
  1. Absorbed from the small intestine
  2. Food/hyperglycemia may reduce absorption
  3. Significant binding with PP - 90-99% (may interact with other drugs)
  4. Excreted in the urine (*elderly patients/renal/hepatic insufficiency)
  5. Cross placenta
  6. Stimulate fetal beta-cells to release insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Sulfonylureas precautions

A
  1. Not recommended for children, pregnant, lactating women.
  2. Contraindicated in patients with allergy to sulfa agents
  3. Not to be used during severe infections, injury, surgery (use insulin)
  4. Therapy is associated with the cardiovascular mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tolbutamide (Orinase)

A
  • least potent
  • onset: 30 min
  • duration: 6-12 h
  • metabolites - inactive
  • excreted renally
  • has diuretic activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Tolazamide (Tolinase)

A
  • onset: 6h
  • duration: 10-14 h (24h)
  • metabolites are weaker than parent compound
  • excreted renally
  • has diuretic activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clorpropamide (Diabinese)

A
  • rapidly absorbed
  • duration: 60 h
  • excreted renally (parent compound/metabolites)
  • can potentiate ADH secretion
  • transient leucopenia
  • disulfiram-like* reaction with alcohol **
  • *disulfiram –>↓ aldehyde dehydrogenase –> ↑acetyl aldehyde**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glipizide (Glucotrol)

A

shortest half-life 2 hours

  • duration 24 hours
  • completely metabolized in liver
  • few adverse effects**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Glimepiride (Amaryl)

A
  • half-life 5 hours
  • duration 24 hours
  • completely metabolized in liver
  • small dose effectively lowers sugar level**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Glyburide (Micronase, DiaBeta)

A
  • duration: 24 h
  • most potent
  • metabolites in liver - little activity
  • has diuretic activity
  • higher incidences of hypoglycemia**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sulfonylureas Adverse Effects

A

3-5% of patients

  1. Hypoglycemia
    - elderly
    - hepatic/renal insufficiency
    - glyburide, chlorpropamide - higher incidence
  2. Cutaneous reactions
    - rashes
    - photosensitivity
  3. GI reactions
  4. Hematological reactions
    - leukopenia
    - thrombocytopenia
    - hemolytic anemia
  5. Inappropriate secretion of ADH / disulfiram-like reaction chlorpropamide)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Meglitinides —– Repaglinide (Prandin TM )

Nateglinide (Starlix TM)

A
  1. Relatively novel drugs. D-phenylalanine derivative
  2. Inhibit ATP-sensitive K+ channels in pancreatic beta-cells
  3. Stimulates the release of insulin within few minutes
  4. Metabolized in liver/Excreted in the bile
  5. Patients with Type-2DM
  6. Act synergistically with metformin and thiazolidinediones,
  7. Act together with sulfonylureas
  8. Act together with NPH insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Meglitinides MOA

A

Inhibit ATP-sensitive K+ channels in pancreatic beta-cells

Stimulates the release of insulin within few minutes

17
Q

Metoformin (Glucophage)

A

Biguanide

Patients with T2DM
Requires presence of insulin
Duration of Action = 6-12hr

18
Q

Biguanides MOA

A
  1. Increased tissue sensitivity to insulin
  2. Increased activity insulin receptor tyrosine kinase activity
  3. Increased activity of post-receptor signaling pathway
  4. Increased function of insulin/glucose sensitive transporters
  5. Increased movement of transporters into the cell membrane
  6. Increased movement of glucose into the skeletal muscles
  7. Increased glycogen synthesis/storage

** increase a bunch of shit, leading to decrease blood glucose)**

19
Q

Biguanides Contraindications

A
  1. Myocardial infarction!!
  2. Septicemia!!!
  3. History of lactic acidosis!!!
  4. Renal disease - can cause lactic acidosis in patients!!!
  5. Hepatic disease
  6. Lung disease
  7. Not to use after intravenous contrast media
  8. Prolonged fast/low calorie diet
20
Q

Biguanides Adverse effects

A

Gi effects

Serum vitamin b12 levels may decline, calcium supplements reverse this

21
Q

Rosiglitazone (Avandia), Pioglitazone, (Actos)

Rosiglitazone (Avandia)

A

Thiazolidinediones

  1. Contraindicated in hepatic disease
  2. Safety in children is not established
  3. Protein binding >99%
  4. Half-life in plasma - 160 hr

*Avandia some report that sig 43% increase risk of Heart attack patient taking

22
Q

Thiazolidinediones MOA

A

Blocks release of new hormone - resisting (Resistance to insulin)

increase glucose transport by enhancing GLUT-4 synthesis

23
Q

Alpha-glucosidase inhibitors

A

orally taken

inhibit enzymatic digestion of carbs in intestine

do not stimulate insulin release, or result in hypoglycemia

monothreapy in older patients

used in combo with oral anti diabetic agents and/or insulin

Contraindications = renal/hepatic disease, intestinal condition

24
Q

Absorbable Alpha-glucosidase inhibitors

A

Miglitol, inhibit Alpha-glucosidase in other body cells

25
Q

Non-Absorbable Alpha-glucosidase inhibitors

A

Acarbose (Precose) inhibits Alpha-glucosidase inhibitors in intestine

26
Q

Amylin Analogs (hormone)

A

Pramlintide (Symlin TM) 2005

Pramlintide is an injectable analogue of a peptide hormone amylin
Amylin is stored with insulin in beta-cells
Amylin is co-secreted with insulin
Inhibits glucagon secretion.

27
Q

Bile Acid Sequestrants

A

Colesevelam hydrochloride (Welchol)

Initially developed as a bile sequestrant and cholesterol-lowering agent

a) Impairs glucose absorption
b) Antihypertensive therapy in Type 2 diabetes

Contraindications:
History of pancreatitis, esophageal, gastric, or intestinal disorders

***Impairs absorption of multiple medications !!!

28
Q

GLP-1 Receptor Agonist

A

Exenatide (Byetta), Liraglutide (Victoza)

In type 2 diabetes the release of GLP-1 is decreased.

As a result glucagon suppression is decreased

Excessive hepatic glucose output occurs – rising plasma glucose level.

Injectable GLP-1 receptor agonists help to restore GLP-1 activity.

29
Q

Exenatide (Byetta)

A
  1. Increases glucose mediated insulin release
  2. Lowers glucagon levels**
  3. Slows gastric emptying
  4. Decreases appetite
  5. Duration of action up to 10 hours
  6. Major adverse effects are vomiting and nausea
  7. In rare cases serious or fatal necrotizing and hemorrhagic pancreatitis
    * Liraglutide: similar to Exenatide; possible thyroid carcinoma risk
30
Q

DPP-4 Inhibitors

A

DPP-4 degrades incretin hormones GLP-1 and GIP.

Inhibition of DPP-4 increases GLP-1 and GIP concentration.

Glucagon secretion is inhibited, and insulin secretion is increased.

Sitagliptin (Januvia TM) 2007
Saxagliptin (Onglyza TM ) 2009
Linagliptin (Trajenta TM ) 2011

31
Q

Glucagon

A
  1. To treat severe hypoglycemia in diabetics
  2. Hypoglycemia may cause neurological damage
  3. Require intact hepatic glycogen stores
  4. Given: I.M., I.V., nasal spray
  5. Improvement is expected in 10 min (to minimize the risk of hypoglycemia)
  6. After initial improvement glucose is given to patient
  7. In severe beta-blocker overdose - the most effective positive inotrope
  8. Increases cardiac cAMP without stimulation of beta-receptors
  9. Typical adverse effects - nausea/vomiting
32
Q

Diazoxide (Proglycem)

A

**Used in treatment of hypertensive emergencies **Used to treat hypoglycemia - orally

  1. Reduces insulin release from pancreas and insulin-secreting tumors
  2. Severe hypoglycemia is prevented
  3. Insulin synthesis is not inhibited; insulin accumulates in beta cells
  4. Highly bound with plasma proteins
  5. Half-life - 48 hours
  6. Typical adverse effects nausea, vomiting Na+ retention, thrombocytopenia, leukopenia

Pharmacology & Medical Chemistry II (43 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions